



INSTITUTIONAL RESEARCH

Healthcare & Biotechnology

COMPANY UPDATE

Member FINRA/SIPC

Toll Free: 866-928-0928 s www.DawsonJames.com s 925 Federal Highway, 6th Floor s Boca Raton, FL 33432

November 29, 2011

Galectin Therapeutics (OTCBB/GALT)

Robert M. Wasserman

Director of Research

561-208-2905

rwasserman@dawsonjames.com

BUY Targeting Hot Liver Disorder Area

Galectin Therapeutics is developing liver fibrosis and cancer therapeutics

Investment Highlights

1) Galectin Therapeutics (Galectin) provided a progress update earlier this month in coordination with the release of their third quarter 2011 earnings results. The Company made significant clinical progress during the recently completed third quarter, specifically: 1) Submitting and having accepted an abstract analyzing Galectin's pre-clinical data on treating fatty liver disease and fibrosis, to be presented next month at the European Association for the Study of the Liver (EASL) in Portugal; and 2) Finalizing a collaboration, supply, marketing and distribution agreement with partner PROCAPS S.A. for the use of GM-CT-01 in metastatic colorectal cancer in Colombia. Subsequent to the quarter end in early November, Galectin further advanced its liver fibrosis clinical program with the establishment of a Liver Fibrosis Clinical Trial Advisory Board, consisting of five US-based key opinion leaders.

2) The Company also reported financial results for Q3/2011 earlier this month, including a net loss of \$2.3 million or (\$0.03) per share. Major expenses in the quarter included \$655,000 for R&D, up from \$313,000 in the prior year period, \$1.4 million in general and administrative expense, an increase over \$900,000 spent in Q3/2010, and \$311,000 in preferred stock dividends and accretion costs, which was less than the \$790,000 recorded in Q3/2010. We estimate that net cash burn for Galectin during the third quarter was approximately \$1.3 million, which was nearly offset by net proceeds from the exercise of stock options and warrants during the quarter. Thus, Galectin retained \$7.9 million in cash and equivalents at the end of September, or approximately six quarters (1.5 years) worth of operating funding at current levels of cash burn, enough to last through the first quarter of 2013.

3) In addition to the clinical progress achieved in the last quarter, investors have a lot to look forward to from Galectin in the near future as well. First, in the Company's **tumor immunology program**,

Current Price \$0.78

Price Target \$4.00

Estimates	F2010A	F2011E	F2012E
Revenues(\$000s)	\$0	\$0	\$9,000
EPS	(\$0.15)	(\$0.16)	(\$0.07)

Stock Data	
52-Week Range	\$0.63-\$1.57
Shares Outstanding (mil.)	77.1
Market Capitalization (mil.)	\$60.1
Enterprise Value (mil.)	\$52.1
Debt to Capital (9/11)	0.0%
Book Value/Share (9/11)	\$0.01
Price/Book	N/A x
Average Trading Volume (3-Month)	80,000
Insider Ownership	19.6%
Institutional Ownership	0.1%
Short interest	240,000
Dividend / Yield	\$0.00/0.0%



Price target and ratings changes over the past 3 yrs:
Initiated - September 6, 2011 - Buy - Price Target \$4.00

Please find Important Disclosures beginning on Page 5.

Galectin expects their clinical partners (The Ludwig Institute and the Universitaires Saint-Luc in Brussels) to begin a Phase I/II trial in late 2011 or early 2012, with top-line results on the first stage of this trial using GM-CT-01 in metastatic melanoma patients available as early as Q4/2012. Second, the Company's partner PROCAPS is targeting Q2/2012 for final approval in **Colombia** for GM-CT-01 in combination with 5-FU for the treatment of metastatic colorectal cancer, with potential product launch to occur later in 2012, as well as potential regulatory filings in additional countries in South and Central America this year. Finally, Galectin is on track to advance its **Liver Fibrosis clinical program** in 2012, starting off with completion of pre-clinical assessment, and followed by initiation of Phase II trials for GM-CT-01 and Phase I and Phase II trials for GR-MD-02. (See Page 4 for a more complete Clinical Program timeline).

4) Going forward, we are projecting that Galectin will incur a net loss of \$2.5 million or (\$0.03) per share in Q4/2011 (due out early next year), similar to the financial results from the third quarter, making a net loss of \$11.5 million or (\$0.16) per share for the 2011 year as a whole. Next year, we anticipate that initial license fees, royalties and product sales from international partnerships totaling \$9.0 million will help reduce net losses for Galectin to \$6.0 million, or (\$0.07) per share in 2012E.

Conclusion/Stock Valuation

Galectin has experienced management, a strong balance sheet, a solid track record of tight cost control and close monitoring of operating cash outflows, and most importantly a deep clinical pipeline with several programs targeting major medical indications (including the currently "hot" liver disorder area) with near-term potential catalysts looming as well. Thus, we are maintaining our BUY rating on GALT shares and 18-24 month price target of \$4.00 per share, based on projected revenues of \$250 million in 2015E, multiplied by a price/revenues multiple of 4.0X and discounted by a 40% annual rate to reflect regulatory and marketing risks. (See page 4 for projections through year 2015E and also our initiation report for GALT dated September 6, 2011.)

Risk Factors

In addition to normal economic and market risk factors that impact most equities and the common risks shared by Galectin with other companies in the industry, we believe an investment in Galectin Therapeutics involves the following risks:

- **FDA and regulatory risks** – Galectin is subject to regulatory review for its ongoing research and development activities, principally the US Food and Drug Administration but also potentially with other regulatory agencies as well, specifically in South and Central America and potentially Europe.
- **Reliance on joint venture partners** — At present, Galectin has signed one marketing and development partnership, with PROCAPS S.A. for chemotherapy applications in Colombia. In the future, Galectin may sign additional marketing and/or development partnerships for other jurisdictions or pipeline products. Partnerships and joint ventures bring certain risks that are not present in internal operations, however, such as potential delays, company disagreements, or unforeseen financial difficulties at the partnering entity.
- **Need to defend patents and other intellectual property** – At December 31, 2010, Galectin held five patents in the US with additional patents pending in the US as well as in foreign jurisdictions including Europe, Canada, Latin America and Asia. The Company may need to defend its patents in the US and overseas in the future, particularly if one or more products receive regulatory approval and are successfully marketed.

- **Need to raise additional capital** - Currently, Galectin has enough cash on hand to fund ongoing research and marketing development programs into calendar 2013, approximately. However, the Company does not have a history of profitable operations and unforeseen events including potential delays in regulatory approvals and/or product launches could require Galectin to raise additional capital through the sale of equity within a shorter time-frame, therefore potentially diluting current shareholders.
- **Limited stock liquidity** – Trading volume in Galectin stock is comparatively light at an average of 80,000 shares per day. As such, news regarding Galectin, its target market, and/or competitors could lead to significant volatility in the stock price. In addition, GALT shares currently trade on the Nasdaq Over-the-Counter Bulletin Board, and there can be no assurance that these shares will be able to move up to a larger, more active exchange in the future.

Galectin Therapeutics, Inc.
Consolidated Statements of Income
(in \$000s, except EPS)

Robert M. Wasserman

FYE December	2009A	2010A	2011E	2012E	2013E	2014E	2015E
Revenues							
Product revenues - US	\$0	\$0	\$0	\$0	\$0	\$0	\$85,000
Product revenues - International	0	0	0	4,000	7,000	48,000	140,000
License fees, royalties & other	0	0	0	5,000	5,000	10,000	25,000
Total revenues	0	0	0	9,000	12,000	58,000	250,000
Cost of goods sold				1,000	1,750	12,000	56,250
Gross profit				8,000	10,250	46,000	193,750
Expenses							
Research and development	1,110	1,066	3,500	4,500	9,000	18,000	36,000
General and administrative	4,983	3,817	5,750	7,500	15,000	30,000	60,000
One-time and other	0	0	0	0	0	0	0
Total operating expenses	6,093	4,883	9,250	12,000	24,000	48,000	96,000
Loss from operations	(6,093)	(4,883)	(9,250)	(4,000)	(13,750)	(2,000)	97,750
Interest income	3	6	20	50	50	50	50
Interest expense	0	0	0	0	0	0	0
Other expense, net	(1,372)	(752)	(520)	(500)	(500)	(500)	(500)
Net income (loss) before taxes	(7,462)	(5,629)	(9,750)	(4,450)	(14,200)	(2,450)	97,300
Income taxes	0	0	0	0	0	0	38,920
Net income (loss)	(7,462)	(5,629)	(9,750)	(4,450)	(14,200)	(2,450)	58,380
Preferred stock dividends and accretion	(1,957)	(3,080)	(1,750)	(1,500)	(1,500)	(1,500)	(1,500)
Net loss applicable to common stockholders	(9,419)	(8,709)	(11,500)	(5,950)	(15,700)	(3,950)	56,880
Basic and diluted income (loss) per share	(\$0.20)	(\$0.15)	(\$0.16)	(\$0.07)	(\$0.17)	(\$0.04)	\$0.57
Basic and diluted shares outstanding	48,274	56,301	72,000	85,000	90,000	95,000	100,000
Key ratios:							
Revenue growth					33.3%	383.3%	331.0%
Gross Margin				75.0%	75.0%	75.0%	75.0%
R&D/revenues				50.0%	75.0%	31.0%	14.4%
General & admin/revenues				83.3%	125.0%	51.7%	24.0%
Tax Rate				N/A	N/A	N/A	40.0%
Cash Flow/share	(\$0.12)	(\$0.06)	(\$0.09)	(\$0.01)	(\$0.12)	\$0.01	\$1.01

Balance Sheets

(\$000s)

	12/31/10	9/30/11
Assets:		
Cash and equivalents	\$5,891	\$7,944
Grant receivable	234	0
Prepaid expenses & other assets	70	51
Total current	6,195	7,995
Property & equip., net	7	7
Restricted cash	59	64
Intangible assets and other	39	37
TOTAL ASSETS	\$6,300	\$8,103
Liabilities:		
Accounts payable	\$125	\$198
Accrued expenses & other	585	417
Deferred revenue	200	200
Warrant liabilities & other	861	0
Total current	1,771	815
Other long-term liabilities	12	0
Preferred stock	6,211	6,465
Stockholders' equity (deficiency)	(1,694)	823
TOTAL LIAB & EQ	\$6,300	\$8,103

Investor Catalyst Timeline

2010 2011E 2012E

Cancer Therapy

International - Colombia - Colorectal

Submission of regulatory approval	Q4/11	
Marketing approval		Q2/12

US - GM-CT-01

Phase III protocol approval	Q4/10	
Phase III trial initiated		Mid-2012

Liver fibrosis

GM-CT-01

Pre-IND meeting		Q2/12
Submit IND		Q3/12
Initiate Phase II		Q4/12

GM-MD-02

Pre-IND meeting		Q2/12
Submit IND		Q3/12
Initiate Phase I		Q4/12
Initiate Phase II		Q4/12

Tumor Immunology Program

Phase I/II trial initiated	Q4/11orQ1/12	
Top-line results released		Q4/12

Source: Dawson James Securities, Inc. estimates; Company documents

Important Disclosures:

Price Chart:



Price target and ratings changes over the past 3 years:

Initiated – September 6, 2011 – Buy – Price Target \$4.00

Analyst Certification: The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) All Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Dawson James has not received investment banking compensation from the company mentioned in this report but may actively seek compensation for investment banking services in the future. Dawson James does not make a market in this security. Neither the research analyst whose name appears on this report nor any member of his household is an officer, director or advisory board member of the company. Dawson James did not receive any other compensation from the company in the previous 12 months. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future, but the firm as a whole does not beneficially own 1% or more of any class of common equity securities of the subject company.

Ratings definitions: 1) **Buy:** the stock is expected to appreciate and produce a total return of at least 20% over the next 12-18 months; 2) **Neutral:** the stock is fairly valued for the next 12-18 months; and 3) **Sell:** the stock is expected to decline at least 20% over the next 12-18 months and should be sold.

Ratings Distribution	Company Coverage		Investment Banking	
	# of Companies	% of Total	# of Companies	% of Totals
Buy	27	84%	8	30%
Neutral	4	13%	3	75%
Sell	1	3%	0	0%
Total	32	100%	11	34%

Information about valuation methods and risks can be found in the “STOCK VALUATION” and “RISKS” sections of this report.

DAWSON JAMES SECURITIES, INC., Member SIPC, FINRA, (the "Firm") does not make a market in these securities. The Firm may perform or seek to perform investment banking services for these companies in the future. Analysts receive no direct compensation in connection with the firm's investment banking business. All Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report. The Firm, its officers, directors, analysts or employees may effect transactions in and have long or short positions in the securities (or options or warrants with respect thereto) mentioned herein. Although the statements of fact in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice. The Firm may effect transactions as principal or agent in the securities mentioned herein. The securities discussed or recommended in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.